You are here

  • Home
  • Archive
  • Volume 15, Issue Suppl 3
  • First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

Article metrics

Article menu
Download PDFPDF
Articles
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

 

Online download statistics by month:

Online download statistics by month: December 2018 to February 2023

AbstractFullPdf
Dec 2018600
Jan 20191000
Feb 20191101
Mar 2019500
Apr 2019100
May 2019600
Jul 2019400
Aug 2019200
Sep 20191500
Oct 2019200
Nov 2019200
Dec 20191000
Jan 20201000
Feb 2020400
Mar 20202200
Apr 20201400
May 20201000
Jun 2020200
Jul 2020600
Aug 2020200
Sep 2020200
Oct 2020200
Nov 2020200
Dec 20202400
Jan 2021400
Feb 20211000
Mar 2021600
Apr 2021200
Oct 20211000
Nov 2021400
Dec 2021400
Jan 20221200
Feb 20221800
Mar 20221200
Apr 2022800
May 20224600
Jun 20224200
Jul 20222000
Aug 20224600
Sep 20223000
Oct 20223800
Nov 20221400
Dec 20221400
Jan 20231000
Feb 20236400
Total58801